Pre-clinical combination of a PARP inhibitor, talazoparib, and carboplatin in triple-negative breast cancer.

被引：0

作者：

Cotte, Alexia ^{[1
]}

Beniey, Michele ^{[1
]}

Haque, Takrima ^{[2
]}

Bechir, Nelly ^{[2
]}

Hubert, Audrey ^{[1
]}

Diallo, Korotoum W. ^{[1
]}

Tran-Thanh, Danh ^{[2
]}

Hassan, Saima N. ^{[1
]}

机构：

[1] Univ Montreal, Ctr Rech Univ Montreal CRCHUM, Montreal, PQ H3C 3J7, Canada

[2] Ctr Rech Univ Montreal CRCHUM, Montreal, PQ, Canada

来源：

CANCER RESEARCH | 2021年 / 81卷 / 13期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1066

引用

页数：2

共 50 条

[31] Judy Garber on PARP inhibitors for triple-negative breast cancer [J].

Garber, Judy .

ONCOLOGY-NEW YORK, 2017, 31 (11) :814-+

[32] Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial [J].

Loibl, Sibylle ;

O'Shaughnessy, Joyce ;

Untch, Michael ;

Sikov, William M. ;

Rugo, Hope S. ;

McKee, Mark D. ;

Huober, Jens ;

Golshan, Mehra ;

von Minckwitz, Gunter ;

Maag, David ;

Sullivan, Danielle ;

Wolmark, Norman ;

McIntyre, Kristi ;

Lorenzo, Jose J. Ponce ;

Metzger Filho, Otto ;

Rastogi, Priya ;

Symmans, W. Fraser ;

Liu, Xuan ;

Geyer, Charles E., Jr. .

LANCET ONCOLOGY, 2018, 19 (04) :497-509

[33] Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer [J].

Liang, Hongyan ;

Tan, Antoinette R. .

IDRUGS, 2010, 13 (09) :646-656

[34] Identification and evaluation of a novel PARP1 inhibitor for the treatment of triple-negative breast cancer [J].

Gong, Rong ;

Ma, ZhongYe ;

He, LinHao ;

Jiang, ShiLong ;

Cao, DongSheng ;

Cheng, Yan .

CHEMICO-BIOLOGICAL INTERACTIONS, 2023, 382

[35] Synergistic chemosensitivity of triple-negative breast cancer cell lines to a PARP inhibitor, cisplatin and gemcitabine [J].

Hastak, Kedar ;

Alli, Elizabeth ;

Ford, James .

CANCER RESEARCH, 2009, 69

[36] PRMT5 inhibitor synergizes with PARP inhibitors in triple-negative breast cancer cells [J].

Suresh, Samyuktha ;

McPherson, Lisa A. ;

Ford, James M. .

CANCER RESEARCH, 2024, 84 (06)

[37] Synergistic strategies: ADC-PARP inhibitor combinations in triple-negative breast cancer therapy [J].

Rejili, Mokhtar .

PATHOLOGY RESEARCH AND PRACTICE, 2025, 272

[38] PLK1 inhibition overcomes PARP inhibitor resistance in triple-negative breast cancer [J].

Siraj, Abdul K. ;

Poyil, Pratheesh Kumar ;

Padmaja, Divya ;

Parvathareddy, Sandeep Kumar ;

Alobaisi, Khadija ;

Begum, Rafia ;

Almalik, Osama ;

Al-Dayel, Fouad ;

Al-Kuraya, Khawla S. .

CANCER RESEARCH, 2024, 84 (06)

[39] Preclinical efficacy of dasatinib in combination with PARP inhibitor plus standard cytotoxic agent in triple-negative breast cancer xenograft model [J].

Sun, Y. ;

Lin, X. ;

Carlson, Jh ;

De, P. ;

Dey, N. ;

Williams, C. ;

Leyland-Jones, B. .

CANCER RESEARCH, 2017, 77

[40] MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple-negative breast cancer cells [J].

Zeng, Xiaoqi ;

Jiang, Shanshan ;

Ruan, Simin ;

Guo, Zhaoze ;

Guo, Jingyun ;

Liu, Minfeng ;

Ye, Changsheng ;

Dong, Jianyu .

MOLECULAR MEDICINE REPORTS, 2021, 24 (02)

← 1 2 3 4 5 →